The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine ...

Nasal spray offers an alternative for patients ... this is exactly the response required.” As part of the approval process, the FDA asked Belhaven Biopharma to determine if one dose of Nasdepi ...

Note: After the FDA approves a drug ... for an upper respiratory infection or allergy. Because these are also nasal sprays, it is important to take these medicines at least 1 hour before taking ...